Keywords:
Cannabinoids; Developmental disability; Neurodevelopmental disorder; Neuropsychiatric disorders; Paediatrics
Abstract:
A better understanding of the endocannabinoid system and a relaxation in regulatory control of cannabis globally has increased interest in the medicinal use of cannabinoid-based products (CBP). We provide a systematic review of the rationale and current clinical trial evidence for CBP in the treatment of neuropsychiatric and neurodevelopmental disorders in children and adolescents.